EP0973903A2 - Protein for inhibiting apoptosis - Google Patents

Protein for inhibiting apoptosis

Info

Publication number
EP0973903A2
EP0973903A2 EP98928120A EP98928120A EP0973903A2 EP 0973903 A2 EP0973903 A2 EP 0973903A2 EP 98928120 A EP98928120 A EP 98928120A EP 98928120 A EP98928120 A EP 98928120A EP 0973903 A2 EP0973903 A2 EP 0973903A2
Authority
EP
European Patent Office
Prior art keywords
protein
dna
flip
apoptosis
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98928120A
Other languages
German (de)
French (fr)
Inventor
Peter Krammer
Marcus Peter
Carsten Scaffidi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of EP0973903A2 publication Critical patent/EP0973903A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a protein which is suitable for inhibiting apoptosis, a DNA which encodes such a protein and a method for producing such a DNA.
  • the invention further relates to the use of the DNA and the protein and antibodies directed against the protein.
  • Apoptosis is programmed cell death. This is e.g. used by the immune system to ward off harmful substances such as viruses. To do this, virus-specific T lymphocytes attack those cells in the body that are virus-infected and kill them by releasing apoptosis-induced proteins such as perforin.
  • the T lymphocytes can also express the CD95 (APO-1 / Fas) ligand, as a result of which cell death occurs via the CD95 pathway. This route involves binding of the CD95 ligand to the CD95 receptor, which then interacts with the adapter protein FADD, thereby inducing the "recruitment” and activation of the protease FLICE at the DISC ("Death-Inducing Signaling Complex").
  • the present invention is therefore based on the object of providing an agent with which apoptosis can be inhibited. According to the invention, this is achieved by the subject matter in the claims.
  • the present invention thus relates to a protein which is suitable for inhibiting apoptosis, the protein having the amino acid sequence of FIG.
  • the present invention is based on the knowledge of the applicant that in animals, especially mammals, especially humans, there is a protein which can inhibit apoptosis.
  • This protein comprises the amino acid sequence of FIG. 1 or an amino acid sequence different therefrom by one or more amino acids.
  • the applicant has also recognized that the protein interacts with the adapter protein FADD, as a result of which the "recruitment” and the activation of the protease FLICE at the DISC are inhibited.
  • FLIP FLICE inhibitor protein
  • Another object of the present invention is a coding for FLIP
  • Nucleic acid This can be an RNA or a DNA.
  • the latter can e.g. be a genomic DNA or a cDNA.
  • a DNA is preferred which comprises the following:
  • hybridizing DNA indicates a DNA which, under normal conditions, in particular at 20 ° C. below the melting point of the DNA, also DNA from (a) hybridizes.
  • the DNA of FIG. 1 was obtained from the DSM (German Collection of Microorganisms and Cell Cultures) as C-FLIP / 2 / W23795 and C-FLIP / 1 / AA1 1 5792 under DSM 1 1488 and DSM 1 1487 on March 25th 1 997 deposited.
  • DSM German Collection of Microorganisms and Cell Cultures
  • a DNA according to the invention is described below in the form of a cDNA. This is an example of every DNA covered by the present invention.
  • a cDNA according to the invention can be produced by customary methods.
  • a cDNA according to the invention can be present in a vector or expression vector.
  • examples of such are known to the person skilled in the art.
  • an expression vector for E. coli these are e.g. pGEMEX, pUC derivatives, pGEX-2T, pET3b and pQE-8.
  • yeast e.g. to call pY100 and Ycpad l
  • animal cells e.g. pKCR, pEFBOS, cDMB, pCEV4 and pEFrsFLAG must be specified.
  • the baculovirus expression vector pAcSGHisNT-A is particularly suitable for expression in insect cells.
  • suitable cells for expressing a cDNA according to the invention which is present in an expression vector.
  • suitable cells include the E. coli strains HB1 01, DH 1, x1 776, JM 1 01, JM 109, BL21 and SG 1 3009, the yeast strain Saccharomyces cerevisiae and the animal cells L, 3T3, FM3A, CHO, COS, Vero, HeLa and BJAB as well as the insect cells sf9.
  • a cDNA according to the invention is converted into a Expression vector must be inserted. He is also aware that this DNA can be inserted in conjunction with a DNA coding for another protein or peptide, so that the cDNA according to the invention can be expressed in the form of a fusion protein.
  • Another object of the present invention is an antibody directed against an above protein or fusion protein.
  • Such an antibody can be prepared by conventional methods. It can be polyclonal or monoclonal. It is cheap to make it, especially animals
  • the present invention makes it possible to investigate apoptosis and its effects, in particular in certain diseases, such as AIDS, autoimmune diseases and neurodegenerative diseases, in detail.
  • a nucleic acid according to the invention in particular a DNA, and primers derived therefrom, it can be determined in mammals, in particular humans, whether they contain and / or express a gene which codes for a FLIP protein in the above sense.
  • the person skilled in the art uses customary methods such as
  • kits which contains a protruding nucleic acid, in particular DNA, and / or primers derived therefrom as well as carriers and customary auxiliaries.
  • the present invention is also suitable for inhibiting apoptosis. This is particularly important for diseases such as AIDS and neurodegenerative diseases.
  • a FLIP protein according to the invention can be introduced into mammals, especially humans. For this purpose, it may be beneficial to use FLIP on a protein that is not considered foreign by the respective body, e.g. Transferrin or BSA to couple.
  • a nucleic acid according to the invention, in particular a DNA can also be introduced into mammals, in particular humans, and expressed there. For this purpose, it may be advantageous to place the expression of the nucleic acid according to the invention under the control of a tissue-specific promoter. Vectors necessary for the expression of a
  • Nucleic acid in mammals are known to those skilled in the art. Furthermore, the expression of FLIP can be controlled and regulated with an antibody according to the invention. The antibody can also be present in the kit above.
  • the present invention thus represents a major contribution to the diagnostic and therapeutic detection of apoptotic processes.
  • the diagnostic detection can take place not only post- but also prenatally.
  • FIG. 1 shows the base sequence and the amino acid sequence derived therefrom, which is comprised by a FLIP protein according to the invention.
  • the outlined sequence gives a DED (Death Effector Domain) -
  • Fig. 1 is found in DSM 1 1 488.
  • 2 shows the base sequence and the amino acid sequence derived therefrom which is encompassed by a FLIP protein according to the invention.
  • the sequence of Fig. 2 can be found in DSM 1 1487.
  • FIG. 3 shows in (A) the expression of a FLIP protein according to the invention in cells. Due to the FLAG tag portion, the FLIP protein according to the invention (FLIP-FLAG) shows a slower running behavior than the FLIP protein expressed endogenously by the cells.
  • FLIP-FLAG shows a slower running behavior than the FLIP protein expressed endogenously by the cells.
  • Example 1 Production and purification of a FLIP protein according to the invention
  • the DNA from FIG. 1 is provided with Bam HI linkers, cut with Bam HI and inserted into the expression vector pQE-8 (Diagen) cleaved with Bam HI.
  • the expression plasmid pQ / FLIP is obtained.
  • pQ / FLIP is used to transform E.coli SG 1 3009 (cf. Gottesmann, S. et al., J. Bacteriol. 148, (1 981), 265-273).
  • the bacteria are in an LB medium with 10 ⁇ g / ml ampicillin and
  • the bound fusion protein is eluted in a pH 3.5 buffer. After neutralization, the fusion protein is a 1 8% SDS polyacrylamide Subject to gel electrophoresis and stained with Coomassie blue (cf. Thomas, JO and Kornberg, RD, J. Mol. Biol. 1 49 (1 975), 709-733).
  • Example 2 Production and detection of an antibody according to the invention
  • a fusion protein according to the invention from example 1 is subjected to a 1 8% SDS-polyacrylamide gel electrophoresis. After staining the gel with 4 sts
  • 35 ⁇ g of gel-purified fusion protein in 0.7 ml of PBS and 0.7 ml of complete or incomplete Freund's adjuvant are used per immunization.
  • the rabbit's serum is tested in an immunoblot.
  • a fusion protein according to the invention from Example 1 is subjected to an SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose filter (cf. Khyse-
  • the western Blot analysis is carried out as in Bock, C.-T. et al., Virus Genes 8, (1 994), 21 5-229.
  • the nitrocellulose filter is incubated with a first antibody at 37 ° C. for 1 h.
  • This antibody is rabbit serum (1: 1 000 in PBS).
  • the nitrocellulose filter is incubated with a second antibody.
  • This antibody is an alkaline phosphatase-linked monoclonal goat anti-rabbit IgG antibody (Dianova) (1: 5000) in PBS.
  • Antibodies are extracted from egg yolk and tested in a Western blot. Polyclonal antibodies according to the invention are detected.
  • Example 3 Expression of a FLIP protein according to the invention in cells and its action
  • the DNA of FIG. 2 is provided with ExoR5 / Xbal linkers, cut with EcoRI and Xbal and inserted into the expression vector pEFrsFLAG cleaved with the same restriction enzymes.
  • the expression plasmid pEFrsFLAG-FLIP is obtained. This codes for a fusion protein FLAG-FLIP from a FLAG tag (N-terminus partner) and the FLIP protein according to the invention from FIG. 2 (C-terminus partner).
  • pEFrsFLAG-FLIP is used to transfect human BJAB cells. Extracts are obtained from transfected cells and electrophoresed on an SDS polyacrylamide gel. A Western blot method is then carried out in which a monoclonal antibody from Example 2 is used for the detection of the expressed FLIP protein. An anti-mouse antibody is used to detect the antibody binding (cf. FIG. 3A).
  • a FLIP protein according to the invention can be expressed in cells and detected by an antibody according to the invention.
  • the above BJAB cells transfected with pEFrs FLAG-FLIP are treated untreated or treated with 10 ng / ml anti-APO-1 for 16 hours at 37 ° C. Treatment with anti-APO-1 mediates CD95
  • the amount of apoptotic cells is determined by determining the DNA fragmentation (see FIG. 3B).
  • CD95-mediated apoptosis can be inhibited by the expression of the FLIP protein according to the invention.
  • BJAB cells and BJAB cells transfected with pEFrsFLAG-FLIP are treated with 1 ⁇ g / ml anti-APO-1.
  • Cell extracts are obtained and electrophoretically separated in an SDS polyacrylamide gel.
  • a Western blot method is then carried out, in which an antibody directed against the protease FLICE is used (cf. FIG. 3C).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a protein which is suitable for inhibiting apoptosis, a DNA coding said protein and a method for producing the protein. The invention also relates to the use of the DNA and the protein, and to antibodies directed against the protein.

Description

Protein zur Inhibierung von Apoptose Protein to inhibit apoptosis
Die vorliegende Erfindung betrifft ein Protein, das sich zur Inhibierung von Apoptose eignet, eine ein solches kodierende DNA und ein Verfahren zur Herstellung eines solchen. Ferner betrifft die Erfindung die Verwendung der DNA und des Proteins sowie gegen das Protein gerichtete Antikörper.The present invention relates to a protein which is suitable for inhibiting apoptosis, a DNA which encodes such a protein and a method for producing such a DNA. The invention further relates to the use of the DNA and the protein and antibodies directed against the protein.
Apoptose ist der programmierte Zelltod. Dieser wird z.B. vom Immunsystem dazu genutzt, schädliche Stoffe, wie Viren, abzuwehren. Hierzu greifen Virusspezifische T-Lymphozyten jene Zellen des Körpers an, die Virus-infiziert sind und töten diese ab, indem sie Apoptose-induzierte Proteine, wie Perforin, freiset- zen. Auch können die T-Lymphozyten den CD95 (APO-1 /Fas)-Liganden exprimie- ren, wodurch der Zelltod über den CD95-Weg abläuft. Dieser Weg umfaßt die Bindung des CD95-Liganden an den CD95-Rezeptor, der dann mit dem Adapterprotein FADD interagiert, wodurch das "Recruitment" und die Aktivierung der Protease FLICE am DISC ("Death-Inducing Signaling Complex") induziert werden.Apoptosis is programmed cell death. This is e.g. used by the immune system to ward off harmful substances such as viruses. To do this, virus-specific T lymphocytes attack those cells in the body that are virus-infected and kill them by releasing apoptosis-induced proteins such as perforin. The T lymphocytes can also express the CD95 (APO-1 / Fas) ligand, as a result of which cell death occurs via the CD95 pathway. This route involves binding of the CD95 ligand to the CD95 receptor, which then interacts with the adapter protein FADD, thereby inducing the "recruitment" and activation of the protease FLICE at the DISC ("Death-Inducing Signaling Complex").
Weitere Arbeiten weisen darauf hin, daß Apoptose auch für die Ausbildung verschiedener Erkrankungen mit verantwortlich ist. Solche Erkrankungen sind z.B. AIDS, Autoimmunerkrankungen und neurodegenerative Erkrankungen. Um gegen diese Erkrankungen vorgehen zu können, wäre es hilfereich, Substanzen zu haben, die Apoptose inhibieren können. Solche Substanzen sind jedoch bisher nur unzureichend bekannt.Further work indicates that apoptosis is also responsible for the development of various diseases. Such diseases are e.g. AIDS, autoimmune diseases and neurodegenerative diseases. In order to deal with these diseases, it would be helpful to have substances that can inhibit apoptosis. So far, however, such substances are not sufficiently known.
Der vorliegenden Erfindung liegt somit die Aufgabe zugrunde, ein Mittel bereitzustellen, mit dem Apoptose inhibiert werden kann. Erfindungsgemäß wird dies durch die Gegenstände in den Patentansprüchen erreicht.The present invention is therefore based on the object of providing an agent with which apoptosis can be inhibited. According to the invention, this is achieved by the subject matter in the claims.
Gegenstand der vorliegenden Erfindung ist somit ein Protein, das sich zur Inhibie- rung von Apoptose eignet, wobei das Protein die Aminosäuresequenz von Fig.The present invention thus relates to a protein which is suitable for inhibiting apoptosis, the protein having the amino acid sequence of FIG.
1 oder eine hiervon durch eine oder mehrere Aminosäuren unterschiedliche Aminosäuresequenz umfaßt.1 or an amino acid sequence different therefrom by one or more amino acids.
Die vorliegende Erfindung beruht auf der Erkenntnis des Anmelders, daß in Tieren, besonders Säugetieren ganz besonders dem Menschen, ein Protein existiert, das Apoptose inhibieren kann. Dieses Protein umfaßt die Aminosäuresequenz von Fig. 1 oder eine hiervon durch eine oder mehrere Aminosäuren unterschiedliche Aminosäuresequenz. Ferner hat der Anmelder erkannt, daß das Protein mit dem Adapterprotein FADD interagiert, wodurch das "Recruitment" und die Aktivierung der Protease FLICE am DISC inhibiert werden.The present invention is based on the knowledge of the applicant that in animals, especially mammals, especially humans, there is a protein which can inhibit apoptosis. This protein comprises the amino acid sequence of FIG. 1 or an amino acid sequence different therefrom by one or more amino acids. The applicant has also recognized that the protein interacts with the adapter protein FADD, as a result of which the "recruitment" and the activation of the protease FLICE at the DISC are inhibited.
In der vorliegenden Erfindung wird vorstehendes Protein mit FLIP ("FLICE-Inhibi- tory-Protein") bezeichnet.In the present invention, the above protein is called FLIP ("FLICE inhibitor protein").
Ein weiterer Gegenstand der vorliegenden Erfindung ist eine für FLIP kodierendeAnother object of the present invention is a coding for FLIP
Nukleinsäure. Dies kann eine RNA oder eine DNA sein. Letztere kann z.B. eine genomische DNA oder eine cDNA sein. Bevorzugt ist eine DNA, die folgendes umfaßt:Nucleic acid. This can be an RNA or a DNA. The latter can e.g. be a genomic DNA or a cDNA. A DNA is preferred which comprises the following:
(a) die DNA von Fig. 1 oder eine hiervon durch ein oder mehrere Basenpaare unterschiedliche DNA,(a) the DNA of FIG. 1 or a DNA different therefrom by one or more base pairs,
(b) eine mit der DNA von (a) hybridisierende DNA, oder(b) a DNA hybridizing with the DNA of (a), or
(c) eine mit der DNA von (a) oder (b) über den degenerierten genetischen Code verwandte DNA.(c) a DNA related to the DNA of (a) or (b) via the degenerate genetic code.
Der Ausdruck "hybridisierende DNA" weist auf eine DNA hin, die unter üblichen Bedingungen, insbesondere bei 20°C unter dem Schmelzpunkt der DNA, mit einer DNA von (a) hybridisert.The term "hybridizing DNA" indicates a DNA which, under normal conditions, in particular at 20 ° C. below the melting point of the DNA, also DNA from (a) hybridizes.
Die DNA von Fig. 1 wurde bei der DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen) als C-FLIP/2/W23795 bzw. C-FLIP/1 /AA1 1 5792 unter DSM 1 1488 bzw. DSM 1 1487 am 25. März 1 997 hinterlegt.The DNA of FIG. 1 was obtained from the DSM (German Collection of Microorganisms and Cell Cultures) as C-FLIP / 2 / W23795 and C-FLIP / 1 / AA1 1 5792 under DSM 1 1488 and DSM 1 1487 on March 25th 1 997 deposited.
Nachstehend wird eine erfindungsgemäße DNA in Form einer cDNA beschrieben. Diese steht beispielhaft für jede unter die vorliegende Erfindung fallende DNA.A DNA according to the invention is described below in the form of a cDNA. This is an example of every DNA covered by the present invention.
Eine erfindungsgemäße cDNA kann durch übliche Verfahren hergestellt werden.A cDNA according to the invention can be produced by customary methods.
Günstig ist es von einer humanen Expressions-Bibliothek auszugehen und diese mit der DNA von Fig. 1 , insbesondere mit Primern, die den 5'- bzw. 3'-Bereich der umrandeten DNA-Region betreffen, zu screenen. Als Hybridisierungs-Bedin- gungen können übliche, insbesondere vorstehend angegebene, gewählt werden. Positive Klone können dann auf ihre Apoptose-Inhibierungsaktivität in üblichenIt is favorable to start from a human expression library and to screen it with the DNA of FIG. 1, in particular with primers which relate to the 5 'or 3' region of the framed DNA region. Conventional, in particular those specified above, can be selected as hybridization conditions. Positive clones can then test for their apoptosis inhibitory activity in the usual way
Verfahren getestet werden.Procedures to be tested.
Eine erfindungsgemäße cDNA kann in einem Vektor bzw. Expressionsvektor vorliegen. Beispiele solcher sind dem Fachmann bekannt. Im Falle eines Ex- pressionsvektors für E.coli sind dies z.B. pGEMEX, pUC-Derivate, pGEX-2T, pET3b und pQE-8. Für die Expression in Hefe sind z.B. pY100 und Ycpad l zu nennen, während für die Expression in tierischen Zellen z.B. pKCR, pEFBOS, cDMB, pCEV4 und pEFrsFLAG anzugeben sind. Für die Expression in Insektenzellen eignet sich besonders der Baculovirus-Expressionsvektor pAcSGHisNT-A.A cDNA according to the invention can be present in a vector or expression vector. Examples of such are known to the person skilled in the art. In the case of an expression vector for E. coli, these are e.g. pGEMEX, pUC derivatives, pGEX-2T, pET3b and pQE-8. For expression in yeast e.g. to call pY100 and Ycpad l, while for expression in animal cells e.g. pKCR, pEFBOS, cDMB, pCEV4 and pEFrsFLAG must be specified. The baculovirus expression vector pAcSGHisNT-A is particularly suitable for expression in insect cells.
Der Fachmann kennt geeignete Zellen, um eine erfindungsgemäße, in einem Expressionsvektor vorliegende cDNA zu exprimieren. Beispiele solcher Zellen umfassen die E.coli-Stämme HB1 01 , DH 1 , x1 776, JM 1 01 , JM 109, BL21 und SG 1 3009, den Hefe-Stamm Saccharomyces cerevisiae und die tierischen Zellen L, 3T3, FM3A, CHO, COS, Vero, HeLa und BJAB sowie die Insektenzellen sf9.The person skilled in the art knows suitable cells for expressing a cDNA according to the invention which is present in an expression vector. Examples of such cells include the E. coli strains HB1 01, DH 1, x1 776, JM 1 01, JM 109, BL21 and SG 1 3009, the yeast strain Saccharomyces cerevisiae and the animal cells L, 3T3, FM3A, CHO, COS, Vero, HeLa and BJAB as well as the insect cells sf9.
Der Fachmann weiß, in welcher Weise eine erfindungsgemäße cDNA in einen Expressionsvektor inseriert werden muß. Ihm ist auch bekannt, daß diese DNA in Verbindung mit einer für ein anderes Protein bzw. Peptid kodierenden DNA inseriert werden kann, so daß die erfindungsgemäße cDNA in Form eines Fusionsproteins exprimiert werden kann.The person skilled in the art knows in what way a cDNA according to the invention is converted into a Expression vector must be inserted. He is also aware that this DNA can be inserted in conjunction with a DNA coding for another protein or peptide, so that the cDNA according to the invention can be expressed in the form of a fusion protein.
Des weiteren kennt der Fachmann Bedingungen, transformierte bzw. trans- fizierte Zellen zu kultivieren. Auch sind ihm Verfahren bekannt, das durch die erfindungsgemäße cDNA exprimierte Protein zu isolieren und zu reinigen. Ein solches Protein, das auch ein Fusionsprotein sein kann, ist somit ebenfalls Gegenstand der vorliegenden Erfindung.Furthermore, the person skilled in the art knows the conditions for cultivating transformed or transfected cells. He is also aware of methods for isolating and purifying the protein expressed by the cDNA according to the invention. Such a protein, which can also be a fusion protein, is thus also the subject of the present invention.
Ein weiterer Gegenstand der vorliegenden Erfindung ist ein gegen ein vorstehendes Protein bzw. Fusionsprotein gerichteter Antikörper. Ein solcher Antiköroer kann durch übliche Verfahren hergestellt werden. Er kann polyklonal bzw. monoklonal sein. Zu seiner Herstellung ist es günstig, Tiere, insbesondereAnother object of the present invention is an antibody directed against an above protein or fusion protein. Such an antibody can be prepared by conventional methods. It can be polyclonal or monoclonal. It is cheap to make it, especially animals
Kaninchen oder Hühner für einen polyklonalen und Mäuse für einen monoklona- len Antikörper, mit einem vorstehenden (Fusions)protein oder Fragment davon zu immunisieren. Weitere "Booster" der Tiere können mit dem gleichen (Fu- sions)protein oder Fragmenten davon erfolgen. Der polyklonale Antikörper kann dann aus dem Serum bzw. Eigelb der Tiere erhalten wrden. Für den monoklona- len Antikörper werden Miizzellen der Tiere mit Myelomzellen fusioniert. Ein erfindungsgemäßer Antikörper, der gegen ein Protein mit der Aminosäuresequenz von Fig. 2 gerichtet ist, wurde als NF6 unter DSM ACC2347 bei der DSM am 1 . April 1 998 hinterlegt.Immunize rabbits or chickens for a polyclonal and mice for a monoclonal antibody with an above (fusion) protein or fragment thereof. Further “boosters” of the animals can be carried out using the same (fusion) protein or fragments thereof. The polyclonal antibody can then be obtained from the serum or egg yolk of the animals. Miiz cells of the animals are fused with myeloma cells for the monoclonal antibody. An antibody according to the invention, which is directed against a protein with the amino acid sequence of FIG. 2, was used as NF6 under DSM ACC2347 at the DSM on the 1st April 1 998.
Die vorliegende Erfindung ermöglicht es, Apoptose und ihre Wirkung, insbesondere bei bestimmten Erkrankungen, wie AIDS, Autoimmunerkrankungen und neurodegenerativen Erkrankungen, im Detail zu untersuchen. Mit einer erfindungsgemäßen Nukleinsäure, insbesondere einer DNA, und hiervon abgeleiteten Primern, kann in Säugetieren, insbesondere dem Menschen, festgestellt werden, ob sie ein Gen enthalten und/oder exprimieren, das für ein FLIP-Protein im vorstehenden Sinne kodiert. Hierzu wird der Fachmann übliche Verfahren, wieThe present invention makes it possible to investigate apoptosis and its effects, in particular in certain diseases, such as AIDS, autoimmune diseases and neurodegenerative diseases, in detail. With a nucleic acid according to the invention, in particular a DNA, and primers derived therefrom, it can be determined in mammals, in particular humans, whether they contain and / or express a gene which codes for a FLIP protein in the above sense. To this end, the person skilled in the art uses customary methods such as
BERICHTIGTES BLATT (REGEL 91) ISA/EP Reverse Transkription, PCR-Reaktion, Hybridisierung und Sequenzierung, durchführen. Erfindungsgemäß wird auch ein Kit bereitgestellt, der eine vorstehende Nukleinsäure, insbesondere DNA, und/oder hiervon abgeleitete Primer sowie Träger und übliche Hilfsstoffe enthält.CORRECTED SHEET (RULE 91) ISA / EP Perform reverse transcription, PCR reaction, hybridization and sequencing. According to the invention, a kit is also provided which contains a protruding nucleic acid, in particular DNA, and / or primers derived therefrom as well as carriers and customary auxiliaries.
Ferner eignet sich die vorliegende Erfindung, Apoptose zu inhibieren. Dies hat insbesondere bei Erkrankungen, wie AIDS und neurodegenerativen Erkrankungen, eine große Bedeutung. Ein erfindungsgemäßes FLIP-Protein kann in Säugetieren, insbesondere den Menschen, eingebracht werden. Hierzu kann es günstig sein, FLIP an ein vom jeweiligen Körper nicht als fremd angesehenes Protein, z.B. Transferrin oder BSA, zu koppeln. Auch kann eine erfindungsgemäße Nukleinsäure, insbesondere eine DNA, in Säugetieren, insbesondere den Menschen, eingebracht und dort exprimiert werden. Hierzu kann es günstig sein, die Expression der erfindungsgemäßen Nukleinsäure unter die Kontrolle eines Gewe- be-spezifischen Promotors zu stellen. Vektoren, die für die Expression einerThe present invention is also suitable for inhibiting apoptosis. This is particularly important for diseases such as AIDS and neurodegenerative diseases. A FLIP protein according to the invention can be introduced into mammals, especially humans. For this purpose, it may be beneficial to use FLIP on a protein that is not considered foreign by the respective body, e.g. Transferrin or BSA to couple. A nucleic acid according to the invention, in particular a DNA, can also be introduced into mammals, in particular humans, and expressed there. For this purpose, it may be advantageous to place the expression of the nucleic acid according to the invention under the control of a tissue-specific promoter. Vectors necessary for the expression of a
Nukleinsäure in Säugetieren geeignet sind, sind dem Fachmann bekannt. Desweiteren kann mit einem erfindungsgemäßen Antikörper die Expression von FLIP kontrolliert und reguliert werden. Der Antikörper kann ferner in vorstehendem Kit vorliegen.Nucleic acid in mammals are known to those skilled in the art. Furthermore, the expression of FLIP can be controlled and regulated with an antibody according to the invention. The antibody can also be present in the kit above.
Die vorliegende Erfindung stellt somit einen großen Beitrag zur diagnostischen und therapeutischen Erfassung von apoptotischen Prozessen dar. Die diagnostische Erfassung kann dabei nicht nur post- sondern bereits auch pränatal erfolgen.The present invention thus represents a major contribution to the diagnostic and therapeutic detection of apoptotic processes. The diagnostic detection can take place not only post- but also prenatally.
Kurze Beschreibung der Zeichnung:Brief description of the drawing:
Fig. 1 zeigt die Basensequenz und die davon abgeleitete Aminosäuresequenz, die von einem erfindungsgemäßen FLIP-Protein umfaßt ist. Die umrandete Sequenz gibt eine DED (Death Effector Domain)-1 shows the base sequence and the amino acid sequence derived therefrom, which is comprised by a FLIP protein according to the invention. The outlined sequence gives a DED (Death Effector Domain) -
Region wieder. Die Sequenz von Fig. 1 findet sich in DSM 1 1 488. Fig. 2 zeigt die Basensequenz und die davon abgeleitete Aminosäuresequenz, die von einem erfindungsgemäßlen FLIP-Protein umfaßt ist. Die Sequenz von Fig. 2 findet sich in DSM 1 1487.Region again. The sequence of Fig. 1 is found in DSM 1 1 488. 2 shows the base sequence and the amino acid sequence derived therefrom which is encompassed by a FLIP protein according to the invention. The sequence of Fig. 2 can be found in DSM 1 1487.
Fig. 3 zeigt in (A) die Expression eines erfindungsgemäßen FLIP-Proteins in Zellen. Durch den FLAG-Tag-Anteil zeigt das erfindungsgemäße FLIP-Protein (FLIP-FLAG) ein langsameres Laufverhalten als das von den Zellen endogen exprimierte FLIP-Protein. In (B) wird die Inhi- bierungswirkung des erfindungsgemäßen FLIP-Proteins auf CD95- vermittelte Apoptose und in (C) seine Inhibierungswirkung auf die3 shows in (A) the expression of a FLIP protein according to the invention in cells. Due to the FLAG tag portion, the FLIP protein according to the invention (FLIP-FLAG) shows a slower running behavior than the FLIP protein expressed endogenously by the cells. In (B) the inhibitory effect of the FLIP protein according to the invention on CD95-mediated apoptosis and in (C) its inhibitory effect on the
Aktivierung der Protease FLICE gezeigt.Activation of the protease FLICE shown.
Die vorliegende Erfindung wird durch die nachstehenden Beispiele erläutert.The present invention is illustrated by the following examples.
Beispiel 1 : Herstellung und Reinigung eines erfindungsgemäßen FLIP-ProteinsExample 1: Production and purification of a FLIP protein according to the invention
Zur Herstellung eines erfindungsgemäßen FLIP-Proteins wird die DNA von Fig. 1 mit Bam HI-Linkern versehen, mit Bam Hl nachgeschnitten und in den mit Bam Hl gespaltenen Expressionsvektor pQE-8 (Diagen) inseriert. Es wird das Ex- pressionsplasmid pQ/FLIP erhalten. Ein solches kodiert für ein Fusionsprotein aus 6 Histidin-Resten (N-Terminuspartner) und dem erfindungsgemäßen FLIP-Protein von Fig. 1 (C-Terminuspartner) . pQ/FLIP wird zur Transformation von E.coli SG 1 3009 (vgl. Gottesmann, S. et al., J. Bacteriol. 148, ( 1 981 ), 265-273) ver- wendet. Die Bakterien werden in einem LB-Medium mit 1 0 μg/ml Ampicillin undTo produce a FLIP protein according to the invention, the DNA from FIG. 1 is provided with Bam HI linkers, cut with Bam HI and inserted into the expression vector pQE-8 (Diagen) cleaved with Bam HI. The expression plasmid pQ / FLIP is obtained. Such a code for a fusion protein of 6 histidine residues (N-terminus partner) and the FLIP protein according to the invention from Fig. 1 (C-terminus partner). pQ / FLIP is used to transform E.coli SG 1 3009 (cf. Gottesmann, S. et al., J. Bacteriol. 148, (1 981), 265-273). The bacteria are in an LB medium with 10 μg / ml ampicillin and
25 μg/ml Kanamycin kultiviert und 4 h mit 60 μM Isopropyl-ß-D-Thiogalacto- pyranosid (IPTG) induziert. Durch Zugabe von 6 M Guanidinhydrochlorid wird eine Lyse der Bakterien erreicht, anschließend wird mit dem Lysat eine Chromatographie (Ni-NTA-Resin) in Gegenwart von 8 M Harnstoff entsprechend der Angaben des Herstellers (Diagen) des Chromatographie-Materials durchgeführt.25 μg / ml kanamycin cultivated and induced for 4 h with 60 μM isopropyl-β-D-thiogalactopyranoside (IPTG). Lysis of the bacteria is achieved by adding 6 M guanidine hydrochloride, then chromatography (Ni-NTA resin) is carried out with the lysate in the presence of 8 M urea in accordance with the manufacturer's (Diagen) instructions for the chromatography material.
Das gebundene Fusionsprotein wird in einem Puffer mit pH 3,5 eluiert. Nach seiner Neutralisierung wird das Fusionsprotein einer 1 8 % SDS-Polyacrylamid- Gelelektrophorese unterworfen und mit Coomassie-Blau angefärbt (vgl. Thomas, J.O. und Kornberg, R.D., J.Mol.Biol. 1 49 ( 1 975), 709-733).The bound fusion protein is eluted in a pH 3.5 buffer. After neutralization, the fusion protein is a 1 8% SDS polyacrylamide Subject to gel electrophoresis and stained with Coomassie blue (cf. Thomas, JO and Kornberg, RD, J. Mol. Biol. 1 49 (1 975), 709-733).
Es zeigt sich, daß ein erfindungsgemäßes (Fusions)protein in hochreiner Form hergestellt werden kann.It has been shown that a (fusion) protein according to the invention can be produced in highly pure form.
Beispiel 2: Herstellung und Nachweis eines erfindungsgemäßen AntikörpersExample 2: Production and detection of an antibody according to the invention
Ein erfindungsgemäßes Fusionsprotein von Beipiels 1 wird einer 1 8 % SDS- Polyacrylamid-Gelelektrophorese unterzogen. Nach Anfärbung des Gels mit 4 MA fusion protein according to the invention from example 1 is subjected to a 1 8% SDS-polyacrylamide gel electrophoresis. After staining the gel with 4 sts
Natriumacetat wird eine ca. 20-60 kD Bande aus dem Gel herausgeschnitten und in Phosphat gepufferter Kochsalzlösung inkubiert. Gel-Stücke werden sedimentiert, bevor die Proteinkonzentration des Überstandes durch eine SDS- Polyacrylamid-Gelelektrophorese, der eine Coomassie-Blau-Färbung folgt, be- stimmt wird. Mit dem Gel-gereinigten Fusionsportein werden Tiere wie folgt immunisiert:An approximately 20-60 kD band of sodium acetate is cut out of the gel and incubated in phosphate-buffered saline. Gel pieces are sedimented before the protein concentration of the supernatant is determined by SDS-polyacrylamide gel electrophoresis, which is followed by a Coomassie blue staining. Animals are immunized with the gel-purified fusion sport as follows:
Immunisierungsprotokoll für polyklonale Antikörper im KaninchenImmunization protocol for polyclonal antibodies in rabbits
Pro Immunisierung werden 35 μg Gel-gereinigtes Fusionsprotein in 0,7 ml PBS und 0,7 ml komplettem bzw. inkomplettem Freund's Adjuvans eingesetzt.35 μg of gel-purified fusion protein in 0.7 ml of PBS and 0.7 ml of complete or incomplete Freund's adjuvant are used per immunization.
Tag 0: 1 . Immunisierung (komplettes Freund's Adjuvans)Day 0: 1. Immunization (Freund's Complete Adjuvant)
Tag 1 4 2. Immunisierung (inkomplettes Freund's Adjuvans; icFA) Tag 28 3. Immunisierung (icFA) Tag 56: 4. Immunisierung (icFA) Tag 80: AusblutenDay 1 4 2nd immunization (Freund's incomplete adjuvant; icFA) Day 28 3rd immunization (icFA) Day 56: 4th immunization (icFA) Day 80: Bleeding
Das Serum des Kaninchens wird im Immunoblot getestet. Hierzu wird ein erfin- dungsgemäßes Fusionsprotein von Beispiel 1 einer SDS-Polyacrylamid-Gelelek- trophorese unterzogen und auf ein Nitrocellulosefilter übertragen (vgl. Khyse-The rabbit's serum is tested in an immunoblot. For this purpose, a fusion protein according to the invention from Example 1 is subjected to an SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose filter (cf. Khyse-
Andersen), J., J.Biochem.Biophys. Meth. 1 0, ( 1 984), 203-209) . Die Western Blot-Analyse wird wie in Bock, C.-T. et al., Virus Genes 8, ( 1 994), 21 5-229, beschrieben, durchgeführt. Hierzu wird das Nitrocellulosefilter 1 h bei 37 °C mit einem ersten Antikörper inkubiert. Dieser Antikörper ist das Serum des Kaninchens ( 1 : 1 0000 in PBS) . Nach mehreren Waschschritten mit PBS wird das Nitrocellulosefilter mit einem zweiten Antikörper inkubiert. Dieser Antikörper ist ein mit alkalischer Phosphatase gekoppelter monoklonaler Ziege Anti-Kaninchen- IgG-Antikörper (Dianova) ( 1 :5000) in PBS. Nach 30-minütiger Inkubation bei 37°C folgen mehrere Waschschritte mit PBS und anschließend die alkalische Phosphatase-Nachweisreaktion mit Entwicklerlösung (36 μm 5' Bromo-4-chloro- 3-indolylphosphat, 400 μM Nitroblau-tetrazolium, 100 mM Tris-HCI, pH 9,5,Andersen), J., J.Biochem.Biophys. Meth. 1 0, (1 984), 203-209). The western Blot analysis is carried out as in Bock, C.-T. et al., Virus Genes 8, (1 994), 21 5-229. For this purpose, the nitrocellulose filter is incubated with a first antibody at 37 ° C. for 1 h. This antibody is rabbit serum (1: 1 000 in PBS). After several washing steps with PBS, the nitrocellulose filter is incubated with a second antibody. This antibody is an alkaline phosphatase-linked monoclonal goat anti-rabbit IgG antibody (Dianova) (1: 5000) in PBS. After 30 minutes of incubation at 37 ° C, there are several washing steps with PBS and then the alkaline phosphatase detection reaction with developer solution (36 μm 5 'bromo-4-chloro-3-indolyl phosphate, 400 μM nitroblue tetrazolium, 100 mM Tris-HCl, pH 9.5,
100 mM NaCI, 5 mM MgCI2) bei Raumtemperatur, bis Banden sichtbar werden.100 mM NaCI, 5 mM MgCI 2 ) at room temperature until bands become visible.
Es zeigt sich, daß erfindungsgemäße, polyklonale Antikörper hergestellt werden können.It turns out that polyclonal antibodies according to the invention can be produced.
Immunisierungsprotokoll für polyklonale Antikörper im HuhnImmunization protocol for chicken polyclonal antibodies
Pro Immunisierung werden 40 μg Gel-gereinigtes Fusionsprotein in 0,8 ml PBS und 0,8 ml kompletten bzw. inkomplettem Freund's Adjuvans eingesetzt.40 μg of gel-purified fusion protein in 0.8 ml of PBS and 0.8 ml of complete or incomplete Freund's adjuvant are used per immunization.
Tag 0: 1 . Immunisierung (komplettes Freund's Adjuvans)Day 0: 1. Immunization (Freund's Complete Adjuvant)
Tag 28: 2. Immunisierung (inkomplettes Freund's Adjuvans; icFA)Day 28: 2nd immunization (incomplete Freund's adjuvant; icFA)
Tag 50: 3. Immunisierung (icFA) .Day 50: 3. Immunization (icFA).
Aus Eigelb werden Antikörper extrahiert und im Western Blot getestet. Es werden erfindungsgemäße polyklonale Antikörper nachgewiesen.Antibodies are extracted from egg yolk and tested in a Western blot. Polyclonal antibodies according to the invention are detected.
Immunisierungsprotokoll für monoklonale Antikörper der MausImmunization protocol for mouse monoclonal antibodies
Pro Immunisierung werden 1 2 μg Gel-gereinigtes Fusionsprotein in 0,25 ml PBS und 0,25 ml komplettem bzw. inkompletten Freund's Adjuvans eingesetzt; bei der 4. Immunisierung ist das Fusionsprotein in 0,5 ml (ohne Adjuvans) gelöst.1 2 μg of gel-purified fusion protein in 0.25 ml of PBS and 0.25 ml of complete or incomplete Freund's adjuvant are used per immunization; at After the 4th immunization, the fusion protein is dissolved in 0.5 ml (without adjuvant).
Tag 0: 1 . Immunisierung (komplettes Freund's Adjuvans)Day 0: 1. Immunization (Freund's Complete Adjuvant)
Tag 28 2. Immunisierung (inkomplettes Freund's Adjuvans; icFA) Tag 56 3. Immunisierung (icFA) Tag 84: 4. Immunisierung (PBS) Tag 87: FusionDay 28 2nd immunization (Freund's incomplete adjuvant; icFA) Day 56 3rd immunization (icFA) Day 84: 4th immunization (PBS) Day 87: Fusion
Überstände von Hybridomen werden im Western Blot getestet. Erfindungs- gemäße, monoklonale Antikörper werden nachgewiesen.Supernatants from hybridomas are tested in a Western blot. Monoclonal antibodies according to the invention are detected.
Beispiel 3: Expression eines erfindungsgemäßen FLIP-Proteins in Zellen und seine WirkungExample 3: Expression of a FLIP protein according to the invention in cells and its action
(a) Die DNA von Fig. 2 wird mit ExoR5-/Xbal-Linkern versehen, mit EcoRI und Xbal nachgeschnitten und in den mit den gleichen Restriktionsenzymen gespaltenen Expressionsvektor pEFrsFLAG inseriert. Es wird das Expressionsplasmid pEFrsFLAG-FLIP erhalten. Dieses kodiert für ein Fusionsprotein FLAG-FLIP aus einem FLAG-Tag (N-Terminuspartner) und dem erfindungsgemäßen FLIP-Protein von Fig. 2 (C-Terminuspartner) . pEFrsFLAG-FLIP wird zur Transfektion der humanen Zellen BJAB verwendet. Aus transfizierten Zellen werden Extrakte gewonnen und auf einem SDS-Polyacrylamidgel elektrophoretisch aufgetrennt. Danach wird ein Westernblot-Verfahren durchgeführt, in dem ein monoklonaler Antikör- per von Beispiel 2 zum Nachweis des exprimierten FLIP-Proteins verwendet wird. Zur Detektion der Antikörperbindung wird ein anti-Maus Antikörper verwendet (vgl. Fig. 3A) .(a) The DNA of FIG. 2 is provided with ExoR5 / Xbal linkers, cut with EcoRI and Xbal and inserted into the expression vector pEFrsFLAG cleaved with the same restriction enzymes. The expression plasmid pEFrsFLAG-FLIP is obtained. This codes for a fusion protein FLAG-FLIP from a FLAG tag (N-terminus partner) and the FLIP protein according to the invention from FIG. 2 (C-terminus partner). pEFrsFLAG-FLIP is used to transfect human BJAB cells. Extracts are obtained from transfected cells and electrophoresed on an SDS polyacrylamide gel. A Western blot method is then carried out in which a monoclonal antibody from Example 2 is used for the detection of the expressed FLIP protein. An anti-mouse antibody is used to detect the antibody binding (cf. FIG. 3A).
Es zeigt sich, daß ein erfindungsgemäßes FLIP-Protein in Zellen exprimiert und durch einen erfindungsgemäßen Antikörper nachgewiesen werden kann. (b) Die vorstehenden mit pEFrs FLAG-FLIP transfizierten BJAB-Zellen werden unbehandelt oder mit 1 0 ng/ml anti-APO-1 behandelt 1 6 Studen bei 37 °C inkubiert. Durch die Behandlung mit anti-APO-1 wird CD95-vermittelteIt is shown that a FLIP protein according to the invention can be expressed in cells and detected by an antibody according to the invention. (b) The above BJAB cells transfected with pEFrs FLAG-FLIP are treated untreated or treated with 10 ng / ml anti-APO-1 for 16 hours at 37 ° C. Treatment with anti-APO-1 mediates CD95
Apoptose induziert. Die Menge der apoptotischen Zellen wird mittels Bestimmung der DNA-Fragmentierung bestimmt (vgl. Fig. 3B) .Induced apoptosis. The amount of apoptotic cells is determined by determining the DNA fragmentation (see FIG. 3B).
Es zeigt sich, daß durch die Expression des erfindungsgemäßen FLIP- Proteins CD95-vermittelte Apoptose gehemmt werden kann.It has been shown that CD95-mediated apoptosis can be inhibited by the expression of the FLIP protein according to the invention.
(c) BJAB-Zellen sowie mit pEFrsFLAG-FLIP transfizierte BJAB-Zellen werden mit 1μg/ml anti-APO-1 behandelt. Zellextrakte werden gewonnen und in einem SDS-Polyacrylamidgel elektrophoretisch aufgetrennt. Danach wird ein Westernblot-Verfahren durchgeführt, in dem ein gegen die Protease FLICE gerichteter Antikörper verwendet wird (vgl. Fig. 3C) .(c) BJAB cells and BJAB cells transfected with pEFrsFLAG-FLIP are treated with 1 μg / ml anti-APO-1. Cell extracts are obtained and electrophoretically separated in an SDS polyacrylamide gel. A Western blot method is then carried out, in which an antibody directed against the protease FLICE is used (cf. FIG. 3C).
Es zeigt sich, daß in Zellen, in denen das erfindungsgemäße FLIP-Protein exprimiert ist, die Aktivierung von FLICE, d.h. die Spaltung in die aktive Untereinheit p1 8, verhindert wird. It turns out that in cells in which the FLIP protein according to the invention is expressed, the activation of FLICE, i.e. the splitting into the active subunit p1 8 is prevented.

Claims

Patentansprüche claims
1 . Protein, geeignet zur Inhibierung von Apoptose, wobei das Protein die Aminosäuresequenz von Fig. 1 oder eine hiervon durch eine oder mehrere Aminosäuren unterschiedliche Aminosäuresequenz umfaßt.1 . Protein suitable for inhibiting apoptosis, the protein comprising the amino acid sequence of FIG. 1 or an amino acid sequence different therefrom by one or more amino acids.
2. Protein nach Anspruch 1 , umfassend die Aminosäuresequenz von Fig. 22. The protein of claim 1, comprising the amino acid sequence of FIG. 2
3. DNA, kodierend für das Protein nach Anspruch 1 , wobei die DNA umfaßt: (a) die DNA von Fig. 1 oder eine hiervon durch ein oder mehrere Basenpaare unterschiedliche DNA, (b) eine mit der DNA von (a) hybridisierende DNA oder3. DNA encoding the protein of claim 1, wherein the DNA comprises: (a) the DNA of FIG. 1 or a DNA different therefrom by one or more base pairs, (b) a DNA hybridizing with the DNA of (a) or
(c) eine mit der DNA von (a) oder (b) über den degenerierten genetischen Code verwandte DNA.(c) a DNA related to the DNA of (a) or (b) via the degenerate genetic code.
4. DNA nach Anspruch 3, umfassend die Basensequenz von Fig. 2.4. DNA according to claim 3, comprising the base sequence of FIG. 2.
5. Expressionsplasmid, umfassend die DNA nach Anspruch 3 oder 4.5. Expression plasmid comprising the DNA of claim 3 or 4.
6. Transformante, enthaltend das Expressionsplasmid nach Anspruch 5.6. transformant containing the expression plasmid according to claim 5.
7. Verfahren zur Herstellung des Proteins nach Anspruch 1 oder 2, umfassend die Kultivierung der Transformante nach Anspruch 6 unter geeigneten Bedingungen.7. A method for producing the protein according to claim 1 or 2, comprising culturing the transformant according to claim 6 under suitable conditions.
8. Antikörper, gerichtet gegen das Protein nach Anspruch 1 oder 2.8. Antibody directed against the protein according to claim 1 or 2.
9. Verwendung des Proteins nach Anspruch 1 oder 2 als Reagens zur Inhi bierung von Apoptose.9. Use of the protein according to claim 1 or 2 as a reagent for inhibiting apoptosis.
10. Verwendung der DNA nach Anspruch 3 oder 4 als Reagens zur Diagnose und/oder Inhibierung von Apoptose. Verwendung nach Anspruch 9 oder 1 0, wobei die Apoptose-lnhibierung bei AIDS oder neurodegenerativen Erkrankungen erfolgt. 10. Use of the DNA according to claim 3 or 4 as a reagent for the diagnosis and / or inhibition of apoptosis. Use according to claim 9 or 10, wherein the apoptosis inhibition takes place in AIDS or neurodegenerative diseases.
EP98928120A 1997-04-01 1998-04-01 Protein for inhibiting apoptosis Withdrawn EP0973903A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19713434 1997-04-01
DE19713434A DE19713434C1 (en) 1997-04-01 1997-04-01 Protein to inhibit apoptosis
PCT/DE1998/000940 WO1998044103A2 (en) 1997-04-01 1998-04-01 Protein for inhibiting apoptosis

Publications (1)

Publication Number Publication Date
EP0973903A2 true EP0973903A2 (en) 2000-01-26

Family

ID=7825130

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98928120A Withdrawn EP0973903A2 (en) 1997-04-01 1998-04-01 Protein for inhibiting apoptosis

Country Status (4)

Country Link
EP (1) EP0973903A2 (en)
JP (1) JP2001521378A (en)
DE (1) DE19713434C1 (en)
WO (1) WO1998044103A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1097226A1 (en) * 1998-07-08 2001-05-09 Merck Frosst Canada & Co. Usurpin, a mammalian ded-caspase homologue that precludes caspase-8 recruitment and activation by the cd-95 (fas, apo-1) receptor complex
WO2018133937A1 (en) * 2017-01-19 2018-07-26 Biontech Ag Engineered cells for inducing tolerance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031801A1 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis
US6242569B1 (en) * 1997-02-05 2001-06-05 Tularik, Inc. Regulators of apoptosis
IL120759A0 (en) * 1997-03-03 1997-09-30 Yeda Res & Dev Modulators of the function of fas receptors and other proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9844103A2 *

Also Published As

Publication number Publication date
DE19713434C1 (en) 1998-09-24
WO1998044103A3 (en) 1999-03-18
JP2001521378A (en) 2001-11-06
WO1998044103A2 (en) 1998-10-08

Similar Documents

Publication Publication Date Title
DE19747418C1 (en) Inhibitor protein of the wnt signaling pathway
DE19521046C1 (en) DNA encoding DNase and related vectors, host cells and antibodies
EP0973903A2 (en) Protein for inhibiting apoptosis
DE19611234C1 (en) Tyrosine phosphatase-related protein
EP1015583B1 (en) Protein containing an srcr domain
DE19527552C2 (en) Transketolase-related protein
DE19534763C1 (en) FMR1-related protein
DE19825621C2 (en) Protein for regulating apoptosis
DE19650758C1 (en) PKD1 protein fragments, DNA and antibodies
DE19730997C1 (en) SRCR domain-containing protein
DE19856882C1 (en) New spermatogenesis protein useful for investigation and modulation of spermatogenesis, particularly for diagnosis and treatment of spermatogenesis disorders
WO1999053091A9 (en) Dna coding for gdnf, parts of said dna and gdnf variants
DE19819476C1 (en) Polypeptide with immunogenic properties and modified biological functions of a protein
DE19847364C1 (en) Tumor protein
DE19835910C1 (en) Gene isolated on the short arm of human chromosome 17
DE19845277C1 (en) Wolframin, a transmembrane protein and related DNA useful for diagnosis and therapy of Wolfram Syndrome, especially where there is a tendency to psychiatric disease
DE19644501A1 (en) GABA¶A¶ receptor subunit epsilon-related protein
DE19818680C1 (en) A DNA double strand break repair protein, Nibrin, and related DNA useful for diagnosis and therapy of Nijmegen Breakage Syndrome and other diseases influenced by DNA-double-strand break repair

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991014

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20031017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040428